Detail akcie Bioventix online

Business Summary: Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Bioventix PLC revenues decreased 4% to L13.1M. Net income decreased 6% to L7.6M. Revenues reflect REST OF THE WORLD segment decrease of 9% to L10.7M. Net income also reflects Difference on Foreign Exchange increase from L42K to L170K (expense), Administrative Expenses increase of 3% to L2.1M (expense). Dividend per share decreased from L1.55 to L1.50.